AI Article Synopsis
- Vaccination against hepatitis B in children with Down syndrome is less effective, with only 48.3% showing a positive immune response post-vaccination.
- A study involving 120 Brazilian children with Down syndrome showed no significant difference in vaccine response based on gender or age.
- These findings highlight the need for ongoing monitoring and support for Down syndrome patients receiving the hepatitis B vaccine.
Article Abstract
Background: It has been reported that vaccination against hepatitis B is less effective among people with Down syndrome than in the general population. We aimed to evaluate the rate of seroconversion to hepatitis B vaccine in children with Down syndrome from Brazil.
Methods: A total of 120 people with Down syndrome were included. All of them received the vaccine at intervals of 0, 30 and 180 days and serum samples were tested for the presence of antibodies to the hepatitis B surface antigen (anti-HBs) 30 days after the last dose.
Results: In the studied group, 58.3% (70/120) were male and 41.7% (50/120) female, with the median age of 5 years (range 2-15 years). Fifty-eight of 120 (48.3%) developed anti-HBs after vaccination. No association was found between gender and/or age and vaccine response.
Conclusions: The low rate of seroconversion in response to hepatitis B vaccine suggests that all patients with Down syndrome immunized against hepatitis B should be followed and monitored by clinicians.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/cch.12099 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!